340B Unscripted

This episode is the first part of a series of recordings we are putting together to review the HRSA data request list (DRL).  Rob and Greg discuss DRL item #1 – 340B Policies and Procedures. They’ll review the types of operations that HRSA expects to see outlined in a covered entity’s 340B policies and share some insights into how to manage these documents.

HRSA audit readiness and a detailed overview of the DRL will be the subject of our next SpendMend Pharmacy Webinar in December 2023.  Look for more information on registering for this webinar on our social media pages.

Have a suggested podcast topic?  Email us at [email protected] with your ideas.

In this bonus episode, Rob and Greg review the HRSA notice published on October 27 that addresses the immediate use of 340B drugs in unregistered locations and some hospital considerations in response to the update.

In this episode, Rob is pitted against ChatGPT to answer 340B-related FAQs, including topics like child site registration, GPO prohibition, and HRSA audit findings (17:29). In the intro, Greg and Rob catch up on revised contract pharmacy restrictions and thoughts on recent manufacturer inquiries that 340B entities have been receiving.

Email us questions, comments, or suggested podcast topics at [email protected]!

Rich Bucher, one of the co-founders of Turnkey Pharmacy Solutions, makes a long-awaited appearance on the podcast with Greg and Rob.  Rich and Rob share anecdotes from their early days getting involved in external 340B support (23:26).   Rich also shares some thoughts on 340B topics like GPO Prohibition mitigation strategies (39:13), what to make of the FAQ 4301 developments earlier this year (49:58) and opinions on recent state-enacted laws addressing contract pharmacy provisions (57:49).

In the intro, Greg, Rob, and Rich get caught up on manufacturer restrictions and react to inquiries sent to 340B hospitals from the Senate HELP Committee.

Also, don’t forget to register for an upcoming SpendMend webinar focusing on innovative pharmacy supply chain management:

https://attendee.gotowebinar.com/register/677788879648187232?source=340B+Unscripted

In this episode, Greg and Rob are joined by healthcare attorney Jeff Davis, to discuss how the Medicare drug pricing provisions in the IRA will impact 340B providers.  They’ll go over CMS billing modifier requirements (15:27), share opinions on the financial impact covered entities might experience (38:02), and how various legal challenges to the IRA by the pharma industry may play out (56:29).  They also add some insights around CMS’s proposed Part B payment remedy (1:01:03).

In the intro, Rob catches Greg up on new manufacturer restrictions, and some recent HRSA audit experience related to interpreting data request list (DRL) revisions, and shares some commentary on the current House E&C subcommittee hearing on proposed drug shortage legislation.

Email us questions, thoughts, and ideas for podcast topics at [email protected]!

Rob and Greg continue their conversation with health care attorney and 340B expert Emily Cook (21:05).  They discuss thoughts on the CMS Medicare Part B remedy, provide some commentary on the Inflation Reduction Act (IRA) and its intersection with 340B covered entities, and address an issue that could impact hospital DSH eligibility in the future.

In the intro, Greg and Rob are joined by SpendMend colleague Jennifer Hagen and catch up on recent 340B developments, including updates on manufacturer restrictions, follow-up from a prior question about CAR-T therapy, as well as Spendmend’s reference within an amicus brief filed in the Genesis case. Finally, the team recaps recent changes discovered in the HRSA audit data request list (DRL).

If you have any questions or topic suggestions, please email [email protected].

Rob and Greg are joined by Emily Cook (20:15), an attorney in the health care and 340B space. They discuss a number of 340B topics, including ongoing manufacturer restrictions of contract pharmacies (24:52) as well as legal challenges to HRSA’s patient definition (42:16). This is part one of a two-part series, so look for a future podcast episode with more conversation among Rob, Greg, and Emily.

In the intro, the guys catch up on some news and noteworthy 340B items, including drug shortage legislation, state-level 340B developments, tips on addressing manufacturer repayment notifications, and reminders about hospital-CE recertification. 

Aiden shares the 340B questions sent in by our listeners, and there are some good ones. Questions include opening an in-house retail pharmacy, CAR-T therapy, continuum of care and 190 clinics, the IRA, and a couple of other fun ones.

On our one-year anniversary, we want to thank everyone for listening and for all the encouragement we have received.

Rob and Greg continue to unpack all the great information gathered from the 2023 340B Coalition Summer Conference in Washington D.C.  They chat with coworkers, clients, and friends in the 340B community to share insights from sessions at the Conference.  Guests include SpendMend colleagues Jennifer Hagen (16:54) and Shakita Carter (38:12), as well as 340B hospital experts Erin Leigh (47:12), Nan Kempadoo (1:00:14) and Pooja Shah (1:14:08). 

Submit your questions for Rob and Greg here: https://ww2.spendmend.com/340b-unscripted-qa/

Greg and Rob share highlights from the 340B Coalition Conference in DC. Topics covered include proposed CMS repayment for affected hospitals, Inflation Reduction Act updates, legislative updates, and other worthy conference discussions.